Delving into the Latest Updates on Seqirus Netherlands B.V. with Synapse

概览

疾病领域	数量

感染	4

排名前五的药物类型	数量

预防性疫苗	4
灭活疫苗	3

关联

4

项与 Seqirus Netherlands B.V. 相关的药物

Influenza vaccine (surface antigen, inactivated, prepared in cell cultures)(Seqirus)

靶点-

作用机制

免疫调节剂

在研机构

Seqirus Netherlands B.V.

原研机构

Seqirus Ltd.

在研适应症

H5N1流感 [+1]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

欧盟 [+3]

首次获批日期2024-04-19

Quadrivalent Influenza Vaccine, MF-59 Adjuvanted(CSL)

靶点-

作用机制

免疫刺激剂

在研机构

Seqirus GmbH [+2]

原研机构

CSL Ltd.

在研适应症

流感病毒感染

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

澳大利亚

首次获批日期2019-10-01

Influenza vaccine(Seqirus GmbH)

靶点-

作用机制

免疫刺激剂

在研机构

Seqirus Netherlands B.V. [+1]

原研机构

Seqirus GmbH

在研适应症

流感病毒感染 [+2]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2015-11-24

100 项与 Seqirus Netherlands B.V. 相关的临床结果

登录后查看更多信息

0 项与 Seqirus Netherlands B.V. 相关的专利（医药）

登录后查看更多信息

1

项与 Seqirus Netherlands B.V. 相关的文献（医药）

Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis

作者: Coleman, Brenda ; Haag, Mendel ; Sanderson, Ruth ; McGovern, Ian

Background: Standard dose seasonal influenza vaccines often produce modest immunogenic responses in adults ≥65 years old. MF59 is intended to elicit a greater magnitude and increased breadth of immune response. Objective: To determine the effectiveness of seasonal MF59-adjuvanted trivalent/quadrivalent influenza vaccine (aTIV/aQIV) relative to no vaccination or vaccination with standard or high dose egg-based influenza vaccines among people ≥65 years old. Methods: Cochrane methodological standards and PRISMA-P guidelines were followed. Real-world evidence from non-interventional studies published in peer reviewed journals and grey literature from 1997 through to July 15, 2020, including cluster-randomized trials, were eligible. Two reviewers independently extracted data and risk of bias was assessed using the ROBINS-I tool. Results: Twenty-one studies conducted during the 2006/07-2019/20 influenza seasons were included in the qualitative review; 16 in the meta-analyses. Meta-analysis of test-negative studies found that aTIV reduced medical encounters due to lab-confirmed influenza with pooled estimates of 40.7% (95% CI: 21.9, 54.9; I2=0%) for general practitioner visits and 58.5% (40.7, 70.9; I2=52.9%) for hospitalized patients. The pooled estimate of VE from case-control studies was 51.3% (39.1, 61.1; I2=0%) against influenza- or pneumonia-related hospitalization. The pooled estimates for the relative VE of aTIV for the prevention of influenza related medical encounters were 13.9% (4.2, 23.5; I2=95.9%) compared with TIV, 13.7% (3.1, 24.2; I2=98.8%) compared with QIV, and 2.8% (-2.9, 8.5; I2=94.5%) compared with HD TIV. Conclusions: Among adults ≥65 years aTIV demonstrated significant absolute VE, improved relative VE compared to non-adjuvanted standard-dose TIV/QIV, and comparable relative VE to high-dose TIV.

100 项与 Seqirus Netherlands B.V. 相关的药物交易

登录后查看更多信息

100 项与 Seqirus Netherlands B.V. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年12月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

4

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Influenza vaccine(Seqirus GmbH)	流感病毒感染更多	批准上市
Influenza vaccine, quadrivalent(CSL Ltd.)	流感病毒感染更多	批准上市
Influenza vaccine (surface antigen, inactivated, prepared in cell cultures)(Seqirus)	H5N1流感更多	批准上市
Quadrivalent Influenza Vaccine, MF-59 Adjuvanted(CSL)	流感病毒感染更多	批准上市